Juno aims to bring CAR-T therapy to China with new joint venture

The biotech has partnered with WuXi AppTec to launch a new cell therapy company based in Shanghai. 

By Nicole Gray • April 11, 2016

Activist hedge fund targets Depomed board

Last year Depomed fought off a takeover attempt by Horizon Pharma. Now the hedge fund Starboard Value is demanding greater representation on the company's board, alleging Depomed is restricting shareholder rights. 

By Nicole Gray • April 11, 2016

Relypsa reportedly reviewing buyout offers on renewed interest in hyperkalemia drug

AstraZeneca paid $2.7 billion to acquire competitor ZS Pharma in November 2015.

By Nicole Gray • April 8, 2016

In potential $450 million licensing deal, J&J to develop prostate cancer drug

The company is facing increased competition in the prostate cancer market from Medivation's Xtandi. 

By Nicole Gray • April 7, 2016

Allergan snaps up rights to Alzheimer's drugs in deal with Heptares

The licensing agreement was announced hours after the collapse of Allergan's $160 billion merger with Pfizer.   

By Ned Pagliarulo • April 7, 2016

After merger with Pfizer implodes, Allergan's acquisition options open up

The Irish drugmaker will get a large influx of cash when its divestment with Teva clears U.S. regulatory authorities. 

By Ned Pagliarulo • April 6, 2016

Pfizer calls off $160 billion merger with Allergan

New rules on corporate inversions issued earlier this week by the Treasury made it more difficult for the companies to proceed with the deal. 

By Ned Pagliarulo • April 6, 2016

Nimbus liver drug bought by Gilead for $400M cash plus incentives

The deal could be worth as much as $1.2 billion once milestone payments are included. 

By Nicole Gray • April 5, 2016

Price of success: Medivation reportedly hires JP Morgan to help fend off deal-hungry buyers

The company has recently been targeted by a number of Democratic lawmakers for the high price of its cancer drug Xtandi. 

By Nicole Gray • April 1, 2016

Xenoport sells US rights to psoriasis drug to Dr. Reddy's

CA-based Xenoport has struggled with mixed clinical trial results for its psoriasis candidate and financial woes that led to layoffs. 

By Nicole Gray • March 30, 2016

Sun Pharma expands presence in Japan with $293 million deal for Novartis drugs

The Indian drugmaker will acquire 14 established prescription brands in the deal. 

By Ned Pagliarulo • March 29, 2016

Sprout investors reportedly allege Valeant overpriced Addyi

Angry over low uptake of the libido drug, the investor group is claiming Valeant’s price of $800 a month was twice what Sprout had planned to charge.

By Ned Pagliarulo • March 27, 2016

Biotech IPOs continue as Corvus prices public listing

The immuno-oncology company priced its stock at $15 a share, the low end of its target range.

By Nicole Gray • March 24, 2016

J&J and Genentech partnering in two cancer studies combining Darzalex with atezo

Genentech, a division of Roche, has recently pushed several collaborations combining the anti-PDL1 atezolizumab with other cancer treatments, including Kite's CAR-T therapy. 

By Nicole Gray • March 23, 2016

OptumRx signs on with Walgreens Boots Alliance

The pharmacy will fill 90-day prescriptions for OptumRx at mail-delivery prices starting next year. 

By Nicole Gray • March 18, 2016

Bayer planning new life sciences hub in Cambridge, MA

The drugmaker hopes to further build out its existing network of partnerships with biotechs and research groups in the region. 

By Nicole Gray • March 17, 2016

Cellectis and MabQuest team up to develop new class of anti-PD1 antibodies

The collaboration will explore combining Cellectis' gene-edited CAR-T therapies with the new antibodies. 

By Nicole Gray • March 17, 2016

Valeant acquires Orexigen's obesity drug, stock continues its slide

The company announced the acquisition of European rights to Mysimba the same day it revealed significantly downgraded sales forecasts. 

By Nicole Gray • March 16, 2016

Teva's $40.5 billion generics deal with Allergan hits FTC snag

While the European Commission recently gave the deal a green light, Teva now expects the review by the U.S. Federal Trade Commission to stretch as late as June. 

By Ned Pagliarulo • March 15, 2016

Roche signs potential $1 billion cancer immunotherapy deal with Cambridge biotech

Separately, the FDA boosted the prospects of Roche's bladder cancer drug atezolizumab, granting the immunotherapy priority review status. 

By Ned Pagliarulo • March 15, 2016

Allergan would pay $86M in 'golden parachute' taxes if senior execs dismissed

Allergan previously pledged to reimburse its senior executives if they are let go in the wake of the Pfizer merger. However, Brent Saunders and Bill Meury already have roles in the combined company. 

By Nicole Gray • March 15, 2016

KaloBios sets up funding to clear bankruptcy, acquire Chagas drug

However, the loan offer from Black Horse Capital would be contingent on the dilution of former CEO Martin Shkreli's stake.

By Nicole Gray • March 14, 2016

EC approves Teva's $40.5B deal for Allergan generics arm

The approval by the European Commission sets up a pending decision by the U.S. Federal Trade Commission on the deal's approval there. 

By Ned Pagliarulo • March 10, 2016

Alaska Permanent Fund betting big on biotech startups

The Fund has invested over $280 million into Juno Therapeutics, Codiak BioSciences, and Denali Therapeutics. 

By Nicole Gray • March 4, 2016

Sanofi's generics divestment in the E.U. likely to be delayed

The company is searching for a deal to sell all or some of its generics unit Zentiva, which makes Plavix and Aprovel. 

By Nicole Gray • March 3, 2016